Institute for Stem Cell Biology and Regenerative Medicine, Stanford University, Stanford, CA, United States of America; VA Palo Alto Health Care System, Palo Alto, CA, United States of America.
VA Palo Alto Health Care System, Palo Alto, CA, United States of America; Division of Immunology and Rheumatology, Stanford University, Stanford, CA, United States of America.
Clin Immunol. 2021 Aug;229:108784. doi: 10.1016/j.clim.2021.108784. Epub 2021 Jun 11.
Osteoarthritis (OA), the leading cause of joint failure, is characterized by breakdown of articular cartilage and remodeling of subchondral bone in synovial joints. Despite the high prevalence and debilitating effects of OA, no disease-modifying drugs exist. Increasing evidence, including genetic variants of the interleukin 4 (IL-4) and IL-4 receptor genes, implicates a role for IL-4 in OA, however, the mechanism underlying IL-4 function in OA remains unknown. Here, we investigated the role of IL-4 in OA pathogenesis.
Il4-, myeloid-specific-Il4ra-, and Stat6-deficient and control mice were subjected to destabilization of the medial meniscus to induce OA. Macrophages, osteoclasts, and synovial explants were stimulated with IL-4 in vitro, and their function and expression profiles characterized.
Mice lacking IL-4, IL-4Ra in myeloid cells, or STAT6 developed exacerbated cartilage damage and osteophyte formation relative to WT controls. In vitro analyses revealed that IL-4 downregulates osteoarthritis-associated genes, enhances macrophage phagocytosis of cartilage debris, and inhibits osteoclast differentiation and activation via the type I receptor.
Our findings demonstrate that IL-4 protects against osteoarthritis in a myeloid and STAT6-dependent manner. Further, IL-4 can promote an immunomodulatory microenvironment in which joint-resident macrophages polarize towards an M2 phenotype and efficiently clear pro-inflammatory debris, and osteoclasts maintain a homeostatic level of activity in subchondral bone. These findings support a role for IL-4 modulation of myeloid cell types in maintenance of joint health and identify a pathway that could provide therapeutic benefit for osteoarthritis.
骨关节炎(OA)是关节衰竭的主要原因,其特征是关节软骨破裂和滑液关节的软骨下骨重塑。尽管 OA 患病率高且致残影响大,但目前尚无疾病修饰药物。越来越多的证据表明,白细胞介素 4(IL-4)和 IL-4 受体基因的遗传变异表明 IL-4 在 OA 中起作用,然而,IL-4 在 OA 中的作用机制尚不清楚。在这里,我们研究了 IL-4 在 OA 发病机制中的作用。
IL-4-、髓系特异性-IL-4Ra-和 Stat6-缺陷和对照小鼠接受内侧半月板不稳定以诱导 OA。体外刺激 IL-4 培养巨噬细胞、破骨细胞和滑膜外植体,表征其功能和表达谱。
缺乏 IL-4、髓系细胞中的 IL-4Ra 或 STAT6 的小鼠与 WT 对照相比,软骨损伤和骨赘形成加剧。体外分析表明,IL-4 下调与骨关节炎相关的基因,增强巨噬细胞对软骨碎片的吞噬作用,并通过 I 型受体抑制破骨细胞分化和激活。
我们的发现表明,IL-4 以髓样细胞和 STAT6 依赖的方式保护免受骨关节炎的侵害。此外,IL-4 可以促进免疫调节微环境,其中关节驻留巨噬细胞向 M2 表型极化,并有效地清除促炎碎片,破骨细胞在软骨下骨中保持稳态水平的活性。这些发现支持 IL-4 调节髓样细胞类型在维持关节健康中的作用,并确定了一种可能为骨关节炎提供治疗益处的途径。